Dermata Therapeutics, Inc.

NASDAQ (USD): Dermata Therapeutics, Inc. (DRMA)

Last Price

1.58

Today's Change

+0.15 (10.48%)

Day's Change

1.43 - 1.63

Trading Volume

62,580

Overview

Market Cap

2 Million

Shares Outstanding

1 Million

Avg Volume

2,223,495

Avg Price (50 Days)

2.11

Avg Price (200 Days)

5.45

PE Ratio

-0.08

EPS

-18.73

Earnings Announcement

07-Nov-2024

Previous Close

1.43

Open

1.43

Day's Range

1.43 - 1.635

Year Range

1.29 - 17.85

Trading Volume

63,029

Price Change Highlight

1 Day Change

10.49%

5 Day Change

-7.60%

1 Month Change

-39.69%

3 Month Change

-52.12%

6 Month Change

-74.84%

Ytd Change

-82.15%

1 Year Change

-90.42%

3 Year Change

-99.87%

5 Year Change

-99.87%

10 Year Change

-99.87%

Max Change

-99.87%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of hyperhidrosis and aesthetic conditions. The company was incorporated in 2014 and is headquartered in San Diego, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment